BRPI0408365B8 - compostos heterocíclicos de imunomodulação - Google Patents

compostos heterocíclicos de imunomodulação

Info

Publication number
BRPI0408365B8
BRPI0408365B8 BRPI0408365A BRPI0408365A BRPI0408365B8 BR PI0408365 B8 BRPI0408365 B8 BR PI0408365B8 BR PI0408365 A BRPI0408365 A BR PI0408365A BR PI0408365 A BRPI0408365 A BR PI0408365A BR PI0408365 B8 BRPI0408365 B8 BR PI0408365B8
Authority
BR
Brazil
Prior art keywords
optionally substituted
alk
alkyl
radical
heterocyclic
Prior art date
Application number
BRPI0408365A
Other languages
English (en)
Inventor
Richard Mathews Ian
Original Assignee
Avidex Ltd
Medigene Ag
Medigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305876A external-priority patent/GB0305876D0/en
Priority claimed from GB0319429A external-priority patent/GB0319429D0/en
Application filed by Avidex Ltd, Medigene Ag, Medigene Ltd filed Critical Avidex Ltd
Publication of BRPI0408365A publication Critical patent/BRPI0408365A/pt
Publication of BRPI0408365B1 publication Critical patent/BRPI0408365B1/pt
Publication of BRPI0408365B8 publication Critical patent/BRPI0408365B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

compostos heterocíclicos de imunomodulação. a presente invenção refere-se a compostos da fórmula (i) são inibidores de cd80 e úteis na terapia de imunomodulação: (i) r1 e r3 representam, independentemente h; f, ci; br; -no2; -cn; c1-6 alquila opcionalmente substituída por f ou ci; ou c1-c6 alcóxi, opcionalmente substituído por f; r4 representa um grupo de ácido carboxílico (-cooh) ou um éster do mesmo, ou -c(=o)nr6r7, -nr7c(=o)r6, -nr7c(=o)or6, -nhc(=o)nr7r6 ou nhc(=s)nr7r6 onde: r6 representa h ou um radical da fórmula -(alq)m-q, onde: m é 0 ou 1; alq é um c1-c12 alquileno divalente, opcionalmente substituído, linear ou ramificado, ou radical c2-c12 alquenileno ou c2-c12 alquinileno ou um radical divalente c3-c12 carboxílico, qualquer um dos quais pode conter uma ou mais das ligações -o-, -s- ou -n(r8)- onde r8 representa h ou c1-c4 alquila, c3-c4 alquenila, c3-c4 alquinila ou c3-c6 cicloalquila e q representa h; -nr9r10 onde r9 e r10 representam, independentemente h; c1-c4 alquila; c3-c4 alquenila; c3-c4 alquinila; c3-c6 cicloalquila; um grupo éster; um grupo carbocíclico ou heterocíclico opcionalmente substituído; ou r9 e r10 formam um anel, quando tomados em conjunto com o nitrogênio ao qual estão anexados, o anel sendo opcionalmente substituído; e r7 representa h ou c1-c6 alquila; ou quando tomado em conjunto com o átomo ou átomos ao qual está ligado, ele é anexado a r6 e r7 formando um anal monocíclico opcionalmente substituído, possuindo 5, 6 ou 7 átomos no anel; e x representa uma ligação ou radical divalente da fórmula -(z)n(alq)- ou -(alq)-(z)n- onde z representa -o-, -s- ou -nh-, alq é conforme definido em relação a r6 e n é 0 ou 1.
BRPI0408365A 2003-03-14 2004-03-10 compostos heterocíclicos de imunomodulação BRPI0408365B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0305876A GB0305876D0 (en) 2003-03-14 2003-03-14 Immuno inhibitory heterocyclic compounds
GB0319429A GB0319429D0 (en) 2003-08-19 2003-08-19 Immuno Inhibitory Heterocyclic compounds
PCT/GB2004/001008 WO2004081011A1 (en) 2003-03-14 2004-03-10 Immunomodulating heterocyclic compounds

Publications (3)

Publication Number Publication Date
BRPI0408365A BRPI0408365A (pt) 2006-03-21
BRPI0408365B1 BRPI0408365B1 (pt) 2018-11-21
BRPI0408365B8 true BRPI0408365B8 (pt) 2021-05-25

Family

ID=32992598

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408365A BRPI0408365B8 (pt) 2003-03-14 2004-03-10 compostos heterocíclicos de imunomodulação

Country Status (19)

Country Link
US (3) US7276505B2 (pt)
EP (2) EP1603917B1 (pt)
JP (1) JP4892338B2 (pt)
KR (1) KR101133959B1 (pt)
AT (1) ATE489388T1 (pt)
BR (1) BRPI0408365B8 (pt)
CA (1) CA2519063C (pt)
DE (1) DE602004030225D1 (pt)
DK (1) DK1603917T3 (pt)
EA (2) EA009680B1 (pt)
EC (1) ECSP056104A (pt)
IL (1) IL170389A (pt)
MX (1) MXPA05009667A (pt)
NO (1) NO332136B1 (pt)
NZ (1) NZ541973A (pt)
PL (2) PL1603917T3 (pt)
PT (1) PT1603917E (pt)
SI (1) SI1603917T1 (pt)
WO (1) WO2004081011A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1603917E (pt) * 2003-03-14 2011-02-04 Medigene Ag Compostos heterocíclicos imunomoduladores
GB0325644D0 (en) * 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
DE602004017231D1 (de) * 2004-08-09 2008-11-27 Medigene Ltd Immunmodulierende oxopyrazolocinnoline als cd80-inhibitoren
CA2618888A1 (en) * 2005-08-10 2007-02-15 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
GB0603522D0 (en) * 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition
JP2009530274A (ja) 2006-03-15 2009-08-27 ワイス ヒスタミン−３アンタゴニストとしてのｎ−置換−アザシクリルアミン化合物
EP2027086B1 (en) 2006-05-19 2011-11-16 Wyeth LLC N-benzoyl-pyrrolidin-3-ylamines as histamine-3 antagonists
US20100093867A1 (en) * 2006-07-05 2010-04-15 Ryoichi Matsuda Method Of Treating Genetic Disease Caused By Nonsense Mutation
PE20081152A1 (es) * 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
AR067549A1 (es) 2007-07-16 2009-10-14 Wyeth Corp Compuesto de oxazol,tiazol e imidazol, composicion farmaceutica que lo comprende , proceso para la preparacion del compuesto , uso del compuesto y metodos para la inhibicion del receptor h3 y para el tratamiento de un trastorno cognitivo relacionado con o afectado por el receptor de histamina -3 (h3
EP2020404A1 (en) * 2007-08-01 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Cyanomethyl substituted N-Acyl Tryptamines
WO2009043784A1 (en) 2007-10-04 2009-04-09 F. Hoffmann-La Roche Ag Cyclopropyl aryl amide derivatives and uses thereof
GB201021104D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
EP2676666A1 (en) 2012-06-20 2013-12-25 Eidgenössische Technische Hochschule Zürich (ETH) Compounds for use in diagnosis or therapy of vulnerable atherosclerotic plaques
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
CA2960277A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
EP3558992A4 (en) 2016-12-15 2020-12-02 ONO Pharmaceutical Co., Ltd. TREK CHANNEL ACTIVATOR (K + CHANNELS ASSOCIATED WITH TWIK)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB629412A (en) 1946-12-24 1949-09-20 Geigy Ag J R Manufacture of metallisable monoazo dyestuffs of the pyrazolone series
US3576637A (en) 1967-04-20 1971-04-27 Konishiroku Photo Ind Lith-type of emulsion containing pyrozolone
JPS61161285A (ja) * 1984-12-28 1986-07-21 ルセル−ユクラフ ピラゾロ〔４，３−ｃ〕シンノリン−３−オンの誘導体、それらの塩類、これらの製造法、薬剤としての使用、これらを含有する組成物及び中間体生成物
US4591589A (en) * 1985-01-16 1986-05-27 Roussel Uclaf 2-aryl pyrazolo[4,3-c]cinnolin-3-ones
DE3626221A1 (de) 1986-08-02 1988-02-04 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial zur herstellung farbiger aufsichtsbilder
US4906644A (en) 1986-11-20 1990-03-06 Mitsubishi Kasei Corporation Lipid-peroxide formation inhibiting composition and novel compounds useful therefor
DE3903993A1 (de) 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
ID16283A (id) 1996-03-20 1997-09-18 Astra Pharma Prod Senyawa yang berguna dibidang farmasi
GB9713707D0 (en) 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
SE0102404D0 (sv) * 2001-07-04 2001-07-04 Active Biotech Ab Novel immunomodulating compounds
WO2003004485A1 (fr) 2001-07-05 2003-01-16 Takeda Chemical Industries, Ltd. Composes heterocycles a 5 chainons condenses avec un benzo, leur procede de preparation et leur utilisation
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7081456B2 (en) 2002-11-22 2006-07-25 Active Biotech Ab Immunomodulatory compounds
EP1572689B1 (en) 2002-12-16 2009-03-11 Active Biotech AB Tetracyclic immunomodulatory compounds
PT1603917E (pt) 2003-03-14 2011-02-04 Medigene Ag Compostos heterocíclicos imunomoduladores
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
DE602004017231D1 (de) 2004-08-09 2008-11-27 Medigene Ltd Immunmodulierende oxopyrazolocinnoline als cd80-inhibitoren
US20060221590A1 (en) * 2005-03-31 2006-10-05 Edoardo Campini System and method for Advanced Mezzanine Card connection
GB0603522D0 (en) 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition

Also Published As

Publication number Publication date
CA2519063C (en) 2011-05-10
EP2284172A1 (en) 2011-02-16
MXPA05009667A (es) 2006-01-27
HK1090921A1 (zh) 2007-01-05
DK1603917T3 (da) 2011-02-28
IL170389A (en) 2013-08-29
CA2519063A1 (en) 2004-09-23
BRPI0408365B1 (pt) 2018-11-21
EP1603917A1 (en) 2005-12-14
NZ541973A (en) 2009-06-26
JP4892338B2 (ja) 2012-03-07
ATE489388T1 (de) 2010-12-15
AU2004220310A1 (en) 2004-09-23
KR101133959B1 (ko) 2012-04-09
US7276505B2 (en) 2007-10-02
BRPI0408365A (pt) 2006-03-21
WO2004081011A1 (en) 2004-09-23
ECSP056104A (es) 2006-03-01
KR20050121681A (ko) 2005-12-27
US20080045527A1 (en) 2008-02-21
US20090312334A1 (en) 2009-12-17
PT1603917E (pt) 2011-02-04
EA200501370A1 (ru) 2006-08-25
NO20054710L (no) 2005-12-13
EA014080B1 (ru) 2010-08-30
US7598247B2 (en) 2009-10-06
PL1603917T3 (pl) 2011-12-30
SI1603917T1 (sl) 2011-04-29
PL383655A1 (pl) 2008-04-14
DE602004030225D1 (de) 2011-01-05
EA200702435A1 (ru) 2008-06-30
US8309552B2 (en) 2012-11-13
NO20054710D0 (no) 2005-10-13
EA009680B1 (ru) 2008-02-28
US20070021428A1 (en) 2007-01-25
NO332136B1 (no) 2012-07-02
JP2006520372A (ja) 2006-09-07
EP1603917B1 (en) 2010-11-24

Similar Documents

Publication Publication Date Title
MXPA05009667A (es) Compuestos heterociclicos inmunomoduladores.
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
WO2009150381A3 (fr) Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases
ES2184280T3 (es) Compuestos de indol como inhibidores de cox-2'.
DK0650960T3 (da) Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.
EA200400944A1 (ru) Замещенные производные тетрациклина, фармацевтическая композиция и способ лечения субъекта с их использованием
PE20090151A1 (es) Derivados de pirimidinona y metodos para su uso
UY31986A (es) Derivados n- sustituídos de la 2-metil-propionamida;{1-[5-sustiuido-4-sustituido-tiazol-2-il-carbamoil]-1-metil-etil} amidas de ácidos carboxílicos sustituidos, derivados farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
UY30603A1 (es) Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica
BRPI0412439A (pt) compostos e composições compreendendo esteróis e/ou estanóis e inibidores de biossìntese de colesterol e uso dos mesmos no tratamento ou prevenção de uma variedade de doenças e condições
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
CO6280421A2 (es) Bifosfatos de alquilo de 2 a 5 atomos de carbonoimidazol
AR041882A1 (es) Compuestos de imidazopiridina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen
BRPI0514549A (pt) ácidos de pirrol-naftila como inibidores de pai-1
BRPI0407968A (pt) derivados de oxamida úteis como inibidores de raf-quinase
UY32246A (es) Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica
BR0307033A (pt) ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas
CR7249A (es) Derivados de diamina, proceso para producir los derivados de diamina, y funguicidas que contienen los derivados de diamina como ingrediente activo
DK295989A (da) Insekt- og miderepellanter
AR041678A1 (es) Formas cristalinas de clorhidrato de donepezil
EA201070603A1 (ru) Лекарственное средство, активное в отношении невропатической боли
BR0313000A (pt) Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente
MX12708A (es) Derivados de oxima de 1,2,5,6-tetrahidropiridina yprocedimiento para su preparacion
ATE394371T1 (de) Pyrrolidinesterderivate mit oxytocinmodulierender wirkung
AR035003A1 (es) Derivados de propanolamina relacionados con acidos biliares, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo para la preparacion de medicamentos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MEDIGENE LTD. (GB)

Free format text: NOME ALTERADO DE: AVIDEX LIMITED

B25A Requested transfer of rights approved

Owner name: MEDIGENE AG (DE)

Free format text: TRANSFERIDO DE: MEDIGENE LTD.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.